Show simple item record

dc.contributor.authorGómez-Gómez, E.
dc.contributor.authorJiménez-Vacas, J.M.
dc.contributor.authorPedraza-Arévalo, Sergio
dc.contributor.authorLópez-López, F.
dc.contributor.authorHerrero-Aguayo, V.
dc.contributor.authorHormaechea Agulla, Daniel
dc.contributor.authorValero-Rosa, J.
dc.contributor.authorIbáñez-Costa, Alejandro
dc.contributor.authorLeón González, A.J.
dc.contributor.authorSánchez-Sánchez, Rafael
dc.contributor.authorGónzalez Serrano, T.
dc.contributor.authorRequena-Tapia, M.J.
dc.contributor.authorCastaño, Justo P.
dc.contributor.authorCarrasco-Valiente, J.
dc.contributor.authorGahete Ortiz, Manuel D.
dc.contributor.authorLuque, R.M.
dc.date.accessioned2019-09-06T11:58:17Z
dc.date.available2019-09-06T11:58:17Z
dc.date.issued2019
dc.identifier.urihttp://hdl.handle.net/10396/18985
dc.description.abstractEngrailed variant-2 (EN2) has been suggested as a potential diagnostic biomarker; however, its presence and functional role in prostate cancer (PCa) cells is still controversial or unknown. Here, we analyzed 1) the expression/secretion profile of EN2 in five independent samples cohorts from PCa patients and controls (prostate tissues and/or urine) to determine its utility as a PCa biomarker; and 2) the functional role of EN2 in normal (RWPE1) and tumor (LNCaP/22Rv1/PC3) prostate cells to explore its potential value as therapeutic target. EN2 was overexpressed in our two cohorts of PCa tissues compared to control and in tumor cell lines compared with normal-like prostate cells. This profile was corroborated in silico in three independent data sets [The Cancer Genome Atlas(TCGA)/Memorial Sloan Kettering Cancer Center (MSKCC)/Grasso]. Consistently, urine EN2 levels were elevated and enabled discrimination between PCa and control patients. EN2 treatment increased cell proliferation in LNCaP/22Rv1/PC3 cells, migration in RWPE1/PC3 cells, and PSA secretion in LNCaP cells. These effects were associated, at least in the androgen-sensitive LNCaP cells, with increased AKT and androgen-receptor phosphorylation levels and with modulation of key cancer-associated genes. Consistently, EN2 treatment also regulated androgen-receptor activity (full-length and splicing variants) in androgen-sensitive 22Rv1 cells. Altogether, this study demonstrates the potential utility of EN2 as a non-invasive diagnostic biomarker for PCa and provides novel and valuable information to further investigate its putative utility to develop new therapeutic tools in PCa.es_ES
dc.format.mimetypeapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/es_ES
dc.sourceJournal of Clinical Medicine 8, 1400 (2019)es_ES
dc.subjectEngrailed homeobox variantses_ES
dc.subjectProstate canceres_ES
dc.subjectAggressivenesses_ES
dc.subjectBiomarkeres_ES
dc.titleOncogenic Role of Secreted Engrailed Homeobox 2 (EN2) in Prostate Canceres_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttp://dx.doi.org/10.3390/jcm8091400es_ES
dc.relation.projectIDGobierno de España. PI16/00264es_ES
dc.relation.projectIDGobierno de España. CP15/00156es_ES
dc.relation.projectIDGobierno de España. CM16/00180es_ES
dc.relation.projectIDGobierno de España. BFU2016-80360-Res_ES
dc.relation.projectIDGobierno de España. FPU14/04290es_ES
dc.relation.projectIDJunta de Andalucía. BIO-0139es_ES
dc.relation.projectIDJunta de Andalucía. CTS-1406es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record